ARRY: Short Interest Hits 27% as Index Deletion Pressure Mounts

Array Technologies enters its November 5 earnings print with short interest at its highest level in the recent rebuild, passive index selling looming on two separate timelines, and options traders still positioned as if none of that matters.

Short interest climbed to 27.1% of free float, up 13% on the week and now well above the 25.9% level flagged in last week's note. The move accelerated sharply: shares short rose from roughly 39.5 million on October 26 to 41.4 million on October 27, a single-day jump of 5%. Availability remains at zero, every share in the lending pool is out on loan, matching the 52-week floor and a level that has persisted for weeks without interruption. The cost to borrow tells a different story: at 0.86%, it has barely moved despite maximum tightness. The borrow market is saturated but not under squeeze pressure, a combination that points to a short book that is crowded and comfortable rather than stressed.

Options traders have not moved toward the same conclusion. The put/call ratio closed at 0.153, its lowest reading of the past year and fractionally below even the 52-week low of 0.152. That is deeply call-heavy, almost 1.25 standard deviations below the 20-day average, meaning the options market is expressing more optimism than at almost any point in the past twelve months. The divergence between a 27% short book and a put/call ratio near its all-time low has been a feature of this stock for several weeks. It has now become more extreme, not less.

The Street has spent October cutting targets across the board. BMO Capital trimmed to $6 from $7 on October 21, maintaining Market Perform. JP Morgan dropped to $7 from $8, also maintaining Neutral. Morgan Stanley lowered to $6 from $8. Barclays cut to $4 from $8 in a single move. The mean price target now sits at roughly $7.26, more than double the current price of $3.39. That gap reflects the bull case, which rests on a recovery in revenue growth and an EBITDA multiple that has re-rated from 11x to 13x on 2025 estimates. Bears point to demand softening, margin dilution from international growth, and the company's distance from end customers. The ORTEX short score has climbed to 74.9, its highest reading this month, ranking the stock in just the 3rd percentile for short sentiment across the universe, a heavily shorted name by any measure.

The index deletion timeline adds a mechanical layer of selling pressure that is independent of the fundamental debate. ORTEX forecasts an 81% probability of deletion from the CRSP US Small index at the December 2026 Quarterly Review, which would require the stock to close above $5.74 to avoid. For the MSCI World Small, MSCI USA IMI, and related MSCI small-cap indices, the probability of deletion is 79% and the review stage is already marked as "decided," with a rank date of October 19 already passed. The announcement is due November 11 and the trade date is November 30. Combined forced selling across those indices would amount to roughly $47 million, almost a full day of normal trading volume. That selling is mechanical and does not require a negative fundamental catalyst.

Insider activity from September provides limited signal in this context. The September 24 filings show CEO Kevin Hostetler and other executives exercising options (transaction code M) and withholding shares for tax purposes (transaction code F). No open-market purchases appear in the 90-day window, and the net share figure is zero, suggesting the insider activity was routine compensation mechanics rather than a directional statement.

The last earnings print, on August 5, sent the stock down 12.6% on the day and 13.6% over the following five days. November 5 is therefore the next date that matters most: how much of the short interest rebuilds or unwinds into that print, whether the MSCI deletion announcement on November 11 arrives before or after the market digests results, and whether the options market's call-heavy positioning finds any fundamental basis to stand on.